Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 May 1;152(9):1894-1902.
doi: 10.1002/ijc.34414. Epub 2023 Jan 3.

Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study

Marie Auvray Kuentz  1 , Vincent Hautefeuille  2 , Louis de Mestier  3 , Clélia Coutzac  4 , Thierry Lecomte  5 , Victor Nardon  6 , Pascal Artru  7 , Anthony Turpin  8 , Antoine Drouillard  9 , David Malka  10 , My-Linh Tran-Minh  11 , Isabelle Trouilloud  12 , Astrid Lièvre  13 , Nicolas Williet  14 , Simon Pernot  15 , Yann Touchefeu  16 , Julien Taieb  1 , Pascal Hammel  3 , Aziz Zaanan  1
Affiliations
Free article
Multicenter Study

Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study

Marie Auvray Kuentz et al. Int J Cancer. .
Free article

Abstract

Pancreatic adenosquamous carcinoma (PASC) account for <5% of pancreatic malignancies. The efficacy of modern chemotherapy regimens in patients with advanced PASC is unknown. Patients with advanced PASC from 2008 to 2021 were consecutively included in this retrospective multicenter study. Overall survival (OS) and progression-free survival (PFS) were evaluated by Kaplan-Meier method. Ninety-four PASC from 16 French centers were included (median age, 67.3 years; males, 56.4%; metastatic disease, 85.1%). The first-line treatment was chemotherapy for 79 patients (84.0%) (37 FOLFIRINOX (FX), 7 Gemcitabine-nab paclitaxel (GN) and 35 for all other regimen) or best supportive care (BSC) alone for 15 patients (16.0%). No significant difference was observed between FX and GN in terms of PFS (P = .67) or OS (P = .5). Modern regimens pooled together (FX and GN) as compared to all others chemotherapy regimens showed an improvement of overall response rate (39.5% and 9.7%, P = .002), PFS (median, 7.8 vs 4.7 months, P = .02) and OS (median, 12.7 vs 9.2 months, P = .35). This large study evaluating first-line treatment regimens in advanced PASC suggests that modern regimens as FX or GN may be preferable to all other chemotherapy regimens. These results deserve confirmation in prospective studies.

Keywords: adenosquamous carcinoma; advanced disease; chemotherapy; pancreatic cancer.

PubMed Disclaimer

References

REFERENCES

    1. Katz MHG, Taylor TH, Al-Refaie WB, et al. Adenosquamous versus adenocarcinoma of the pancreas: a population-based outcomes analysis. J Gastrointest Surg. 2011;15(1):165-174.
    1. Boyd CA, Benarroch-Gampel J, Sheffield KM, Cooksley CD, Riall TS. 415 patients with adenosquamous carcinoma of the pancreas: a population-based analysis of prognosis and survival. J Surg Res. 2012;174(1):12-19.
    1. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-188.
    1. Fang Y, Su Z, Xie J, et al. Genomic signatures of pancreatic adenosquamous carcinoma (PASC). J Pathol. 2017;243(2):155-159.
    1. Hester CA, Augustine MM, Choti MA, et al. Comparative outcomes of adenosquamous carcinoma of the pancreas: an analysis of the National Cancer Database. J Surg Oncol. 2018;118(1):21-30.

Publication types